Howard Colman,
MD, PhD
Languages Spoken: English
Howard Colman, MD, PhD, has multiple clinical interests including the treatment of primary and metastatic brain tumors, and the diagnosis and management of neurologic complications of cancer. His clinical research is focused on the development and testing of new therapies for brain tumors. His laboratory interests include the identification of molecular markers of prognosis and treatment response in brain tumors and the role of tumors stem cells in the development and treatment resistance of brain tumors. He is a Jon M. Huntsman Presidential Professor in the Department of Neurosurgery, a member of the multidisciplinary Brain Tumor Research Team, and is Leader of the Center for Neurologic Cancers at Huntsman Cancer Institute (HCI) at the University of Utah. He is also an HCI investigator and a member of the Experimental Therapeutics program.
Clinical Locations
Clinic 3A, Neurology
801-213-4269
Fax: (801) 585-6613
Board Certification and Academic Information
| Academic Departments | Neurosurgery
-
Professor Internal Medicine - Adjunct Professor Neurology - Adjunct Professor |
| Academic Divisions | Adult Neurosurgery Oncology |
| Board Certification | American Board of Psychiatry & Neurology (Neurology) United Council for Neurologic Subspecialties (Neuro-oncology) |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.8/ 5
Care provider's explanation of condition/problem
4.7/ 5
Care provider's effort to include me in decisions
4.7/ 5
Wait time at clinic
4.4/ 5
Care provider's concern for questions & worries
4.7/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
March 25, 2022
HUNTSMAN CANCER CENTER
I absolutely love the physician's I interact with. I have been a patient for a lot of years and have never received anything but the best care. I appreciate the team and all of the staff so much.
UofU Patient
February 18, 2022
HUNTSMAN CANCER CENTER
Great appointment, very happy with my vsisit
UofU Patient
February 16, 2022
HUNTSMAN CANCER CENTER
All good.
UofU Patient
January 28, 2022
HUNTSMAN CANCER CENTER
Good
UofU Patient
December 28, 2021
HUNTSMAN CANCER CENTER
Doctor didn't review my scans beforehand, forgot what I had been diagnosed with and I had to remind him (he missed an entire tumor recovery area). MRI noted something in the scan that he didn't acknowledge. I am going elsewhere for a second opinion on the matter.
UofU Patient
November 28, 2021
HUNTSMAN CANCER CENTER
Dr. Colman and Sean Strope are both amazing. They made sure we understood what we discussed, were straight forward when answering our questions, and ensured that they did everything they could to help us in this process. Dr. Colman even took the time to come back in to our room after we were done talking to tell us that about a pathology result that came back during our visit, which I think many other doctors would have just waited to do until our next visit! This result was something that indicated the tumor will be more responsive to treatment and gave us peace of mind, so the fact that he cared enough to take his time and come back in was amazing.
UofU Patient
November 07, 2021
HUNTSMAN CANCER CENTER
Dr. Coleman seemed to be in a hurry when discussing my MRI and questions. I felt as if I was a general patient he needed to see.
UofU Patient
October 24, 2021
HUNTSMAN CANCER CENTER
Professional, respectful, provided information, listened to my health questions, and highly recommend.
UofU Patient
August 12, 2021
HUNTSMAN CANCER CENTER
It is apparent that Dr. Colman and Sean Strope are both very knowledgeable, caring, and thorough. They take every question seriously and never make me feel rushed. I especially appreciate the fact that I am shown all of the MRI imaging so that I can see for myself what we are dealing with. I also appreciate how thorough the explanations are of the tumor board discussions and appreciate the lengths to which everyone at Huntsman goes to collaborate and provide the highest standard of care.
UofU Patient
August 06, 2021
HUNTSMAN CANCER CENTER
Dr Coleman and PA are awesome! Glad to have them!
UofU Patient
August 06, 2021
HUNTSMAN CANCER CENTER
I appreciate everyone's engagement!
UofU Patient
April 18, 2021
HUNTSMAN CANCER CENTER
Dr. Coleman is great!
UofU Patient
April 11, 2021
HUNTSMAN CANCER CENTER
good
UofU Patient
April 10, 2021
HUNTSMAN CANCER CENTER
As usual they were all very professional and concerned while including my opinion.
UofU Patient
April 06, 2021
HUNTSMAN CANCER CENTER
My Dr seemed to be in a hurry during our appointment
UofU Patient
April 04, 2021
HUNTSMAN CANCER CENTER
I like my drs and their staff
UofU Patient
March 26, 2021
HUNTSMAN CANCER CENTER
Really glad I have been able to work with Dr. Coleman and Sean, they are very attentive and I trust they have my best interest in hand
UofU Patient
March 03, 2021
HUNTSMAN CANCER CENTER
Doctor communicated clearly, was easy to talk to, gave me confidence in his understanding of my situation.
UofU Patient
February 26, 2021
HUNTSMAN CANCER CENTER
HCI Doctor's, Nurses, PA's, and Medical Assistant's are highly recommended and care about my health.
UofU Patient
February 13, 2021
HUNTSMAN CANCER CENTER
Dr Colman and Dr Strope are the best. They make us feel like [NAME REMOVED] is the most important person they are treating and always go the extra mile to answer any questions or concerns we have. We know they have busy schedules but they never make us feel rushed or uncared for. They have made a hard time easier for [NAME REMOVED].
UofU Patient
February 02, 2021
HUNTSMAN CANCER CENTER
good
UofU Patient
January 27, 2021
HUNTSMAN CANCER CENTER
awesome!!!
UofU Patient
November 20, 2020
HUNTSMAN CANCER CENTER
especially appreciated the PA's attentiveness and expertise
UofU Patient
November 19, 2020
HUNTSMAN CANCER CENTER
I think I have the best Doctor's available to anyone. thank you
UofU Patient
November 15, 2020
HUNTSMAN CANCER CENTER
provider suggested several options, but I didn't leave with that information in hand.
UofU Patient
October 30, 2020
HUNTSMAN CANCER CENTER
positive follow up
UofU Patient
October 19, 2020
HUNTSMAN CANCER CENTER
Good
UofU Patient
October 12, 2020
HUNTSMAN CANCER CENTER
Everything about the visit and personnel was like a well-oiled machine...
UofU Patient
October 07, 2020
HUNTSMAN CANCER CENTER
Everyone was amazing!
UofU Patient
August 19, 2020
HUNTSMAN CANCER CENTER
Highly recommend! Everyone cares about my current, previous, and future health.
UofU Patient
July 29, 2020
HUNTSMAN CANCER CENTER
good
Howard Colman, MD, PhD, has multiple clinical interests including the treatment of primary and metastatic brain tumors, and the diagnosis and management of neurologic complications of cancer. His clinical research is focused on the development and testing of new therapies for brain tumors. His laboratory interests include the identification of molecular markers of prognosis and treatment response in brain tumors and the role of tumors stem cells in the development and treatment resistance of brain tumors. He is a Jon M. Huntsman Presidential Professor in the Department of Neurosurgery, a member of the multidisciplinary Brain Tumor Research Team, and is Leader of the Center for Neurologic Cancers at Huntsman Cancer Institute (HCI) at the University of Utah. He is also an HCI investigator and a member of the Experimental Therapeutics program.
Academic Locations
Board Certification and Academic Information
| Academic Departments | Neurosurgery
-
Professor Internal Medicine - Adjunct Professor Neurology - Adjunct Professor |
| Academic Divisions | Adult Neurosurgery Oncology |
| Board Certification | American Board of Psychiatry & Neurology (Neurology) United Council for Neurologic Subspecialties (Neuro-oncology) |
Research Interests
- Brain Tumors
- Clinical Trials
- Role of Tumors Stem Cells in the Development and Treatment Resistance of Brain Tumors
- Development and Testing of New Therapies for Brain Tumors
- Identification of Molecular Markers of Prognosis and Treatment Response in Brain Tumors
Education History
| Fellowship | University of Texas M.D. Anderson Cancer Center Neuro-Oncology Fellow, 2002 |
| Chief Resident | Washington University School of Medicine Neurology Chief Resident, 2001 |
| Residency | Barnes-Jewish Hospital, Washington University School of Medicine Neurology Resident, 2001 |
| Internship | Barnes-Jewish Hospital, Washington University School of Medicine Medicine Intern, 1998 |
| Doctoral Training | Washington University School of Medicine Neuroscience Ph.D., 1997 |
| Professional Medical | Washington University School of Medicine Medicine M.D., 1997 |
| Undergraduate | Brown University Neural Sciences Sc.B., 1989 |
Selected Publications - Journal Articles
Journal Article
- de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S, Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed H, Monga V (2022). Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial. Neuro Oncol.
- Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2022). Factors associated with changes in exercise behaviors during the COVID-19 pandemic. Cancer Causes Control.
- Ellingson BM, Gerstner ER, Lassman AB, Chung C, Colman H, Cole PE, Leung D, Allen JE, Ahluwalia MS, Boxerman J, Brown M, Goldin J, Nduom E, Hassan I, Gilbert MR, Mellinghoff IK, Weller M, Chang S, Arons D, Meehan C, Selig W, Tanner K, Yung WKA, van den Bent M, Wen PY, Cloughesy TF (2022). Hypothetical Generalized Framework for a New Imaging Endpoint of Therapeutic Activity in Early Phase Clinical Trials in Brain Tumors. Neuro Oncol.
- Peoples AR, Oswald LB, Ose J, Daniels B, Himbert C, Hathaway CA, Gigic B, Kirchhoff AC, Lin T, Grossman D, Tward J, Varghese TK Jr, Figueiredo JC, Toriola AT, Beck A, Scaife C, Shibata D, LaStayo P, Gonzalez B, Salas K, Ashworth A, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM (2022). Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions. J Rural Health.
- Brat DJ, Aldape K, Bridge JA, Canoll P, Colman H, Hameed MR, Harris BT, Hattab EM, Huse JT, Jenkins RB, Lopez-Terrada DH, McDonald WC, Rodriguez FJ, Souter LH, Colasacco C, Thomas NE, Yount MH, van den Bent MJ, Perry A (2022). Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. Arch Pathol Lab Med, 146, 547-574.
- Griguer CE, Oliva CR, Coffey CS, Cudkowicz ME, Conwit RA, Gudjonsdottir AL, Ecklund DJ, Fedler JK, Neill-Hudson TM, Nabors LB, Benge M, Hackney JR, Chase M, Leonard TP, Patel T, Colman H, de la Fuente M, Chaudhary R, Marder K, Kreisl T, Mohile N, Chheda MG, McNeill K, Kumthekar P, Dogan A, Drappatz J, Puduvalli V, Kowalska A, Graber J, Gerstner E, Clark S, Salacz M, Markert J (2021). Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neurooncol Adv, 4(1), 1-10.
- Singh K, Batich KA, Wen PY, Tan AC, Bagley SJ, Lim M, Platten M, Colman H, Ashley DM, Chang SM, Rahman R, Galanis E, Mansouri A, Puduvalli VK, Reardon DA, Sahebjam S, Sampson JH, Simes J, Berry DA, Zadeh G, Cloughesy TF, Mehta MP, Piantadosi S, Weller M, Heimberger AB, Khasraw M (2021). Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clin Cancer Res.
- Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H, Cohen AL, Ormond DR, Chakravarti A, Willmarth N, Menon J, Ma J, Bauer H, Watanabe AH, Ulrich CM, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner D (2022). Caregiver burden by treatment and clinical characteristics of patients with glioblastoma. Support Care Cancer, 30(2), 1365-1375.
- Tan AC, Bagley SJ, Wen PY, Lim M, Platten M, Colman H, Ashley DM, Wick W, Chang SM, Galanis E, Mansouri A, Khagi S, Mehta MP, Heimberger AB, Puduvalli VK, Reardon DA, Sahebjam S, Simes J, Antonia SJ, Berry D, Khasraw M (2021). Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer, 9(7).
- Wang X, Haaland B, Hu-Lieskovan S, Colman H, Holmen SL (2021). First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma. Cancer Rep (Hoboken), 4(6), e1419.
- Holowatyj AN, Viskochil R, Ose D, Tingey B, Haaland B, Wilson D, Larson M, Feltz S, Lewis MA, Colman H, Ulrich CM (2020). Diabetes, Body Fatness, and Insulin Prescription Among Adolescents and Young Adults with Cancer. J Adolesc Young Adult Oncol, 10(2), 217-225.
- Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, Tate M, Schwartz M, Zuckerman L, Lezon R, Lukas RV, Jovanovic B, McCortney K, Colman H, Chen S, Lai B, Antipova O, Deng J, Li L, Tommasini-Ghelfi S, Hurley LA, Unruh D, Sharma NV, Kandpal M, Kouri FM, Davuluri RV, Brat DJ, Muzzio M, Glass M, Vijayakumar V, Heidel J, Giles FJ, Adams AK, James CD, Woloschak GE, Horbinski C, Stegh AH (2020). A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Sci Transl Med, 13(584).
- Ellingson BM, Brown MS, Boxerman JL, Gerstner ER, Kaufmann TJ, Cole PE, Bacha JA, Leung D, Barone A, Colman H, van den Bent MJ, Wen PY, Alfred Yung WK, Cloughesy TF, Goldin JG (2020). Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials. Neuro Oncol, 23(2), 189-198.
- Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon DA (2020). Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res, 27(4), 1048-1057.
- Colman H (2020). Adult Gliomas. Continuum (Minneap Minn), 26(6), 1452-1475.
- Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR (2020). A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro Oncol, 22(10), 1505-1515.
- Werner CK, Nna UJ, Sun H, Wilder-Romans K, Dresser J, Kothari AU, Zhou W, Yao Y, Rao A, Stallard S, Koschmann C, Bor T, Debinski W, Hegedus AM, Morgan MA, Venneti S, Baskin-Bey E, Spratt DE, Colman H, Sarkaria JN, Chinnaiyan AM, Eisner JR, Speers C, Lawrence TS, Strowd RE, Wahl DR (2020). Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. Mol Cancer Ther, 19(10), 2163-2174.
- Cohen AL, Anker CJ, Johnson B, Burt LM, Shrieve DC, Salzman K, Jensen R, Boucher K, Colman H (2020). Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial. J Neurooncol, 148(3), 577-585.
- Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN, Giannini C, Holland EC, Jenkins RB, Kleinschmidt-DeMasters B, Komori T, Kros JM, Louis DN, McLean C, Perry A, Reifenberger G, Sarkar C, Stupp R, van den Bent MJ, von Deimling A, Weller M (2020). cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol, 139(3), 603-608.
- Smith-Cohn M, Davidson C, Colman H, Cohen AL (2019). Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases. CNS Oncol, 8(4), CNS48.
- Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY (2019). Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery, 85(3), E607-E608.
- Alexander BM, Trippa L, Gaffey S, Arrillaga-Romany IC, Lee EQ, Rinne ML, Ahluwalia MS, Colman H, Fell G, Galanis E, de Groot J, Drappatz J, Lassman AB, Meredith DM, Nabors LB, Santagata S, Schiff D, Welch MR, Ligon KL, Wen PY (2019). Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. JCO Precis Oncol, 3.
- Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL (2019). Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol, 37(9), 741-750.
- Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, OBrien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM (2019). Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med, 25(3), 477-486.
- Hummel S, Kohlmann W, Kollmeyer TM, Jenkins R, Sonnen J, Palmer CA, Colman H, Abbott D, Cannon-Albright L, Cohen AL (2019). The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database. BMC Cancer, 19(1), 190.
- Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB, Cancer Genome Atlas Research Network, Camargo F, Liang H (2018). Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Cell Rep, 25(5), 1304-1317.e5.
- Ippen FM, Colman H, van den Bent MJ, Brastianos PK (2018). Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet? Am Soc Clin Oncol Educ Book, 38(38), 158-167.
- Philip B, Yu DX, Silvis MR, Shin CH, Robinson JP, Robinson GL, Welker AE, Angel SN, Tripp SR, Sonnen JA, VanBrocklin MW, Gibbons RJ, Looper RE, Colman H, Holmen SL (2018). Mutant IDH1 Promotes Glioma Formation In Vivo. Cell Rep, 23(5), 1553-1564.
- Frandsen J, Orton A, Jensen R, Colman H, Cohen AL, Tward J, Shrieve DC, Suneja G (2018). Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. J Neurosurg, 128(4), 1133-1138.
- Colman H (2017). Toward more informative biomarker-based clinical trials in glioblastoma. Neuro Oncol, 19(7), 880-881.
- Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen MC, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Nageswara Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognr L, Klekner A, Hortobgyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuon T, Schller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor MD (2016). Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis [Epub ahead of print]. J Clin Oncol, 34(21), 2468-2477.
- Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M (2016). Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol, 18(4), 557-64.
- Karsy M, Guan J, Jensen R, Huang LE, Colman H (2016). The Impact of Hypoxia and Mesenchymal Transition on Glioblastoma Pathogenesis and Cancer Stem Cells Regulation. World Neurosurg, 88, 222-236.
- Ceccarelli M, et al TCGA Research Network, Colman H (2016). Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell, 146(3), 550-563.
- Sathyan P, Zinn PO, Marisetty AL, Liu B, Kamal MM, Singh SK, Bady P, Lu L, Wani KM, Veo BL, Gumin J, Kassem DH, Robinson F, Weng C, Baladandayuthapani V, Suki D, Colman H, Bhat KP, Sulman EP, Aldape K, Colen RR, Verhaak RG, Lu Z, Fuller GN, Huang S, Lang FF, Sawaya R, Hegi M, Majumder S (2015). Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. J Neurosci, 35(45), 15097-112.
- Yuan S, Lu Y, Yang J, Chen G, Kim S, Feng L, Ogasawara M, Hammoudi N, Lu W, Zhang H, Liu J, Colman H, Lee JS, Li XN, Xu RH, Huang P, Wang F (2015). Metabolic activation of mitochondria in glioma stem cells promotes cancer development through a reactive oxygen species-mediated mechanism. Stem Cell Res Ther, 6(1), 198.
- Balasubramaniyan V, Vaillant B, Wang S, Gumin J, Butalid ME, Sai K, Mukheef F, Kim SH, Boddeke HW, Lang F, Aldape K, Sulman EP, Bhat KP, Colman H (2015). Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting. Oncotarget, 6(31), 31007-17.
- Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM (2015). Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol, 17(8), 1051-63.
- Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, Sulman E, Wang Q, Marini FC, Andreeff M, Colman H, Lang FF (2015). Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells, 33(8), 2400-15.
- Cohen A, Sato M, Aldape K, Mason CC, Alfaro-Munoz K, Heathcock L, South ST, Abegglen LM, Schiffman JD, Colman H (2015). DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Acta Neuropathol Commun, 3, 34.
- The Cancer Genome Atlas Network (2015). Comprehensive and Integrative Genomic Characterization of Diffuse Lower Grade Gliomas DOI: 10.1056/NEJMoa1402121 *Includes Colman, H. N Engl J Med, 372(26), 2481-2498.
- Choi H, Gillespie DL, Berg S, Rice C, Couldwell S, Gu J, Colman H, Jensen RL, Huang LE (2015). Intermittent induction of HIF-1α produces lasting effects on malignant progression independent of its continued expression. PLoS One, 10(4), e0125125.
- Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS, CERN Foundation (2014). Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro Oncol, 17(3), 440-7.
- Karsy M, Neil JA, Guan J, Mahan MA, Colman H, Jensen RL (2015). A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus, 38(3), E4.
- Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, Colman H (2015). Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurg Focus, 38(3), E2.
- Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR, MD Anderson Community Clinical Oncology Program, Brain Tumor Trials Collaborative (2015). Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol, 17(2), 266-73.
- Cohen AL, Colman H (2015). Glioma biology and molecular markers. Cancer Treat Res, 163, 15-30.
- Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014). A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med, 370(8), 699-708.
- Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul D (2014). A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells. Stem Cells, 32(1), 301-12.
- Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WFA, Boddeke HWGM, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP, Aldape K (2013). Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell, 24(3), 331-46.
Review
- Chen R, Cohen AL, Colman H (2016). Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future. [Review]. Curr Treat Options Oncol, 17(8), 42.
- Karsy M, Guan J, Cohen A, Colman H, Jensen RL (2016). Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons. [Review]. Neurosurg Clin N Am, 27(2), 249-60.
Case Report
Editorial
- Colman H (2019). A platform for efficient early evaluation of biomarker-associated therapies in newly diagnosed IDH wild-type, MGMT unmethylated glioblastoma. 21(1), 6-7.
Other
- Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H, Cohen AL, Ormond DR, Chakravarti A, Willmarth N, Menon J, Ma J, Bauer H, Watanabe AH, Ulrich CM, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner D (2021). Correction to: Caregiver burden by treatment and clinical characteristics of patients with glioblastoma. Support Care Cancer (30(2), pp. 1377-1378). Germany.
- Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2021). Impact of the COVID-19 pandemic on exercise habits among cancer patients. Res Sq. United States.
Patent
- University of Texas M.D. Anderson Cancer Center, Colman H, Zhang L, Aldape K (2009). Multigene Assay to Predict Outcome in an Individual with Glioblastoma. U.S. Patent No. PCT/U808/55472. Washington, D.C.:U.S. Patent and Trademark Office.
Global Impact
Service
| 10/01/2015 | Member | GBM International Adaptive Trial Protocol Writing Committee. | China |